59-01-8
59-01-8
Chemical Structure
Kanamycin
Synonym(s): Kanamycin A
- CAS No.: 59-01-8
- Formula:C18H36N4O11
- Molecular Weight:484.50
IUPAC Name: (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-(((1R,2R,3S,4R,6S)-4,6-diamino-3-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: SBUJHOSQTJFQJX-NOAMYHISSA-N
SMILES: O[C@H]1[C@](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)([H])O[C@H](CN)[C@@H](O)[C@@H]1O
Biological Activity: Kanamycin (Kanamycin A) is an antibacterial agent. Kanamycin blocks Kir4.1 channels. Kanamycin inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Kanamycin | 99.87% | Kanamycin (Kanamycin A) is an antibacterial agent. Kanamycin blocks Kir4.1 channels. Kanamycin inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Kanamycin (Standard) | 99.55% | Kanamycin (Standard) (Kanamycin A (Standard)) is the analytical standard of Kanamycin (HY-16566). This product is intended for research and analytical applications. Kanamycin (Kanamycin A) is an antibacterial agent. Kanamycin blocks Kir4.1 channels. Kanamycin inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ribostamycin | 99.89% | Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic. Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Kanamycin sulfate (Standard) | ≥98% | Kanamycin sulfate (Standard) (Kanamycin A sulfate (Standard)) is the analytical standard of Kanamycin sulfate (HY-16566A). This product is intended for research and analytical applications. Kanamycin sulfate (Kanamycin A sulfate) is an antibacterial agent. Kanamycin sulfate blocks Kir4.1 channels. Kanamycin sulfate inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin sulfate produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin sulfate inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin sulfate can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3''-Deamino-3''-hydroxykanamycin B | 3''-Deamino-3''-hydroxykanamycin B (NK-1012-1) is a kanamycin antibiotic. 3''-Deamino-3''-hydroxykanamycin B can be produced by S. tenebrarius. 3''-Deamino-3''-hydroxykanamycin B is effective against E. coli ATCC 25922 and E. coli CCARM 1A020, with MIC values of 128 μg/mL. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tobramycin monosulfate | Tobramycin (Nebramycin Factor 6) monosulfate is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms. Tobramycin monosulfate can be used to pneumonia research caused by Pseudomonas aeruginosa. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tobramycin (Standard) | ≥98% | Tobramycin (Standard) is the analytical standard of Tobramycin. This product is intended for research and analytical applications. Tobramycin (Nebramycin Factor 6) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms.Tobramycin can be used to pneumonia research caused by Pseudomonas aeruginosa. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bekanamycin | 99.91% | Bekanamycin (Kanamycin B) is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus, against an array of Gram-positive and Gram-negative bacterial strain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bekanamycin sulfate | Bekanamycin (Kanamycin B) sulfate is a minor component of the kanamycin complex, an aminoglycoside antibiotic isolated from Streptomyces kanamyceticus, with antibacterial activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ribostamycin sulfate | 99.55% | Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant KD of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nebramycin Ⅳ | Nebramycin IV is an aminoglycoside antibiotic. Nebramycin IV has a broad antibacterial spectrum and has a strong effect on Gram-positive and negative bacteria and mycobacteria. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Kanamycin disulfate | 99.43% | Kanamycin disulfate (Kanamycin A disulfate) is an antibacterial agent. Kanamycin disulfate blocks Kir4.1 channels. Kanamycin disulfate inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin disulfate produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin disulfate inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin disulfate can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morán-Zendejas R, et al. In vitro and in silico characterization of the inhibition of Kir4.1 channels by aminoglycoside antibiotics. British journal of pharmacology. 2020 Oct;177(19):4548-4560.
- [2]. Peng B, et al. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell metabolism. 2015 Feb 03;21(2):249-262. [Content Brief]
- [3]. Brezden A, et al. Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide. Journal of the American Chemical Society. 2016 Aug 31;138(34):10945-9. [Content Brief]
- [4]. Hawkins Jr JE. XLIX The Ototoxicity of Kanamycin. Annals of Otology, et al. 1959 Sep;68(3):698-715.
- [5]. Cai JY, et al. Concentration-dependent dual effects of silibinin on kanamycin-induced cells death in Staphylococcus aureus. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018 Jun;102:782-791.
- [6]. Gao K, et al. Kanamycin Damages Early Postnatal, but Not Adult Spiral Ganglion Neurons. Neurotoxicity research. 2017 Nov;32(4):603-613.
- [7]. John T, et al. How kanamycin A interacts with bacterial and mammalian mimetic membranes. Biochimica et biophysica acta. Biomembranes. 2017 Nov;1859(11):2242-2252.
